Only a third of patients with advanced cancer had molecular testing to help guide the use of targeted therapies, a review of 26,000 patients showed. Overall, 35% of patients' records had evidence of ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

It’s common to wait until something feels “off” before making an appointment to see a healthcare provider. But waiting for noticeable symptoms can mean missing the chance to catch health issues early.

Biomarker testing has the potential to streamline diagnosis, treatment planning, and anticipation of treatment risks, if done right.

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

Cardiovascular diseases remain the leading cause of death worldwide, accounting for nearly 20 million deaths each year. Rapid ...

Advocates fear New York state could be taking a step back when it comes to biomarker testing access for those with Medicaid.

Every year, America’s medical research pipeline produces new treatments, new technologies and new ways to improve patient care. Often, the real challenge is ensuring policy keeps pace with these ...

Given the opportunity, 90% of Americans say they would take a blood biomarker test for Alzheimer’s disease (AD) — even in the absence of symptoms. Notably, 80% say they wouldn’t wait for a physician ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...